论文部分内容阅读
应用免疫组织化学ＬＳＡＢ法，对４０例乳腺癌的Ｐ５３抗癌基因（Ｐ５３）、雌激素受体（ＥＲ）、孕激素受体（ＰＲ）进行了检测，结果显示：Ｐ５３阳性２４例（６０％），ＥＲ阳性２０例（５０％），ＰＲ阳性１５例（３７．５％），其中三项均阳性者７例，而Ｐ５３与ＥＲ均阳性者１４例，Ｐ５３与ＰＲ均阳性者１１例。结果表明：乳腺癌中Ｐ５３阳性率高于良性乳腺肿瘤，差异显著（Ｐ＜０．０１），ＥＲ阳性率随患者年龄增大而升高；５０岁以上患者阳性率明显高于５０岁以下者；而Ｐ５３、ＰＲ的表达与年龄无关。本组研究表明，ＥＲ、ＰＲ阳性患者采用手术治疗和术后放疗、化疗再增加内分泌治疗，可使患者５年、１０年生存率明显提高，而Ｐ５３阳性、ＥＲ阴性的患者无明显疗效。
The immunohistochemistry LSAB method was used to detect the P53 anti-oncogene (P53), estrogen receptor (ER), and progesterone receptor (PR) in 40 cases of breast cancer. The results showed that: P53 positive in 24 cases (60% ) ER positive in 20 cases (50%), PR positive in 15 cases (37.5%), of which three were positive in 7 cases, and P53 and ER were positive in 14 cases, P53 and PR were positive in 11 cases. The results showed that the positive rate of P53 in breast cancer was higher than that in benign breast tumors (P<0.01). The positive rate of ER increased with the age of the patients. The positive rate of patients with over 50 years of age was significantly higher than those under 50 years of age. However, the expression of P53 and PR has nothing to do with age. The study in this group showed that patients with ER and PR positive patients undergoing surgical treatment, postoperative radiotherapy, and chemotherapy and then increased endocrine therapy can significantly improve the 5-year and 10-year survival rate of patients, while patients with P53-positive and ER-negative patients have no significant effect.